Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.20.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Income Statement [Abstract]        
Revenue
General and administrative expense 2,881 1,914 5,566 3,607
Research and development expense 2,133 1,405 4,702 2,856
Total operating expenses 5,014 3,319 10,268 6,463
Loss from operations (5,014) (3,319) (10,268) (6,463)
Other income (expense)        
Interest expense (52)
Change in fair value - Senior Secured Convertible Notes and Senior Convertible Note 2,120 (161) (5,888) (720)
Offering costs - Senior Secured Convertible Note and Senior Convertible Note (200) (610)
Debt extinguishments loss - Senior Secured Convertible Notes (2,750) (259) (3,937) (260)
Other income (expense), net (830) (420) (10,487) (980)
Loss before provision for income tax (5,844) (3,739) (20,755) (7,443)
Provision for income taxes
Net loss - before noncontrolling interest (5,844) (3,739) (20,755) (7,443)
Net loss attributable to noncontrolling interest 266 145 702 314
Net loss - attributable to PAVmed Inc. (5,578) (3,594) (20,053) (7,129)
Less: Series B Convertible Preferred Stock dividends earned (71) (66) (141) (132)
Net loss attributable to PAVmed Inc. common stockholders $ (5,649) $ (3,660) $ (20,194) $ (7,261)
Net loss per share - attributable to PAVmed Inc. - basic and diluted $ (0.12) $ (0.13) $ (0.45) $ (0.26)
Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted $ (0.13) $ (0.13) $ (0.46) $ (0.27)
Weighted average common shares outstanding - basic and diluted 44,781 27,606 44,140 27,344